» Articles » PMID: 39592852

Neoantigen-specific MRNA/DC Vaccines for Effective Anticancer Immunotherapy

Overview
Journal Genes Immun
Date 2024 Nov 26
PMID 39592852
Authors
Affiliations
Soon will be listed here.
Abstract

The development of personalized anticancer vaccines based on neoantigens represents a new direction in cancer immunotherapy. The latest advancement in dendritic cell (DC) tumor vaccine construction involves loading DC with mRNA-encoding neoantigens, which allows for rapid production and is suitable for personalized preparation. Cell-penetrating peptides (CPPs) are emerging as biological delivery systems in which negatively charged nucleic acids can be wound onto the cationic CPP backbone to form nanoscale complexes. This preparation method facilitates standardization. If DC can express and present neoantigen mRNA at high levels, it holds promising application potential. In this study, we developed a neoantigen-mRNA/DC vaccine using candidate neoantigens from mouse colon cancer (MC38) and examined its immune and antitumor effects. The results demonstrated that neoantigen-mRNA/DC vaccines induced strong T cell immune responses and exhibited significant antitumor effects, effectively preventing tumor growth. Our study provides an experimental basis for further optimizing the preparation of DC vaccines and reducing their costs.

References
1.
Lin M, Svensson-Arvelund J, Lubitz G, Marabelle A, Melero I, Brown B . Cancer vaccines: the next immunotherapy frontier. Nat Cancer. 2022; 3(8):911-926. DOI: 10.1038/s43018-022-00418-6. View

2.
Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

3.
Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S . Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002; 20:621-67. DOI: 10.1146/annurev.immunol.20.100301.064828. View

4.
Rowshanravan B, Halliday N, Sansom D . CTLA-4: a moving target in immunotherapy. Blood. 2017; 131(1):58-67. PMC: 6317697. DOI: 10.1182/blood-2017-06-741033. View

5.
Chemnitz J, Parry R, Nichols K, June C, Riley J . SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004; 173(2):945-54. DOI: 10.4049/jimmunol.173.2.945. View